Taha Merghoub
Overview
Explore the profile of Taha Merghoub including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
24833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu K, Abou-Mrad Z, Torkenczy K, Schulze I, Gantchev J, Baquer G, et al.
bioRxiv
. 2025 Mar;
PMID: 40027797
Malignant gliomas follow two distinct natural histories: high grade tumors such as glioblastoma, or lower grade tumors with a propensity to transform into high grade disease. Despite differences in tumor...
2.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al.
Nature
. 2025 Feb;
PMID: 39972124
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may...
3.
Amisaki M, Zebboudj A, Yano H, Zhang S, Payne G, Chandra A, et al.
Nature
. 2025 Jan;
638(8052):1076-1084.
PMID: 39814891
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)-LTβ...
4.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E, et al.
J Hematol Oncol
. 2025 Jan;
18(1):6.
PMID: 39806516
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote...
5.
Robles-Oteiza C, Hastings K, Choi J, Sirois I, Ravi A, Exposito F, et al.
J Exp Med
. 2024 Nov;
222(1.
PMID: 39585348
Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors...
6.
Kim K, Alam S, Kuo F, Chen Z, Yip W, Katims A, et al.
Eur Urol
. 2024 Nov;
87(3):342-354.
PMID: 39550333
Background And Objective: Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed...
7.
Marasco M, Kumar D, Seale T, Borrego S, Kaplun E, Aricescu I, et al.
Cell Rep Med
. 2024 Nov;
5(11):101818.
PMID: 39488215
Neurofibromin (NF1) is a negative regulator of RAS signaling, frequently mutated in cancer. NF1-mutant melanoma is a highly malignant tumor for which targeted therapies are lacking. Here, we use biochemical...
8.
Hackett C, Hirschhorn D, Tang M, Purdon T, Marouf Y, Piersigilli A, et al.
Mol Ther Oncol
. 2024 Sep;
32(3):200862.
PMID: 39308793
Despite therapeutic efficacy observed with immune checkpoint blockade in advanced melanoma, many tumors do not respond to treatment, representing a need for new therapies. Here, we have generated chimeric antigen...
9.
Verma S, Budhu S, Serganova I, Dong L, Mangarin L, Khan J, et al.
J Clin Invest
. 2024 Sep;
134(17).
PMID: 39225102
Tumor reliance on glycolysis is a hallmark of cancer. Immunotherapy is more effective in controlling glycolysis-low tumors lacking lactate dehydrogenase (LDH) due to reduced tumor lactate efflux and enhanced glucose...
10.
Budhu S, Kim K, Yip W, La Rosa S, Jebiwott S, Cai L, et al.
Front Oncol
. 2024 Jul;
14:1405486.
PMID: 38957315
Introduction: Immunotherapy is revolutionizing the management of multiple cancer types. However, only a subset of patients responds to immunotherapy. One mechanism of resistance is the absence of immune infiltrates within...